Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Zevra Therapeutics Inc ZVRA

Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered... see more

Bullboard (NDAQ:ZVRA)

View:
Comment by mevanion Mar 03, 2021 12:13pm

RE:RE:RE:RE:RE:RE:RE:RE:Support?

Congrats!    What a day.   I have been buying the dips.   I will be holding this for a bit here.
Comment by Bobby90on Feb 11, 2021 11:49am

RE:RE:RE:RE:RE:RE:RE:Support?

After approval with 30/13 label I can see a buyout by GPC and that could cost them $3 billion. It's not just a drug with the same potential as Vyvanse ($2.6 billion buyout). KMPH has a pipeline ...more  
Comment by Iseneschalon Feb 04, 2021 1:46pm

RE:RE:RE:RE:RE:RE:Support?

Sounds good......in the mean time..... I just take profits when they stare me in the face.  Good luck to you!  Cheers  ps: I have no position now
Comment by Bobby90on Feb 04, 2021 12:37pm

RE:RE:RE:RE:RE:Support?

If GPC buys them out then we can expect a share price of $30 minimum. New River Pharmaceuticals (Vyvanse) got bought out before approval for $2.6 billion.
Comment by Iseneschalon Feb 04, 2021 12:14pm

RE:RE:RE:RE:Support?

Still in play.......added a small position.  Cheers !
Comment by Iseneschalon Feb 04, 2021 12:00pm

RE:RE:RE:Support?

Has to hold hold here.......here comes the pitch
Comment by Iseneschalon Feb 04, 2021 11:49am

RE:Support?

I treat these runners like a baseball game.... so far there is 2 strikes against KMPH.....so it still can rally from here.... You don't want to be holding on the 3 rd strike.  Cheers !
Post by Iseneschalon Feb 04, 2021 11:45am

Support?

I figure....... $7 has to hold or game over for the short term JMHO
Post by Iseneschalon Feb 04, 2021 11:36am

Sold KMPH......

on the $7.75 failure to break. Crystalized good profit.  I will be back.  Cheers
Comment by Iseneschalon Feb 04, 2021 11:12am

RE:My thoughts for KMPH....

I would like to add that on Jan 25th KMPH sh price double topped at  ~ $7.75.... That would be a crucial pivot.... JMHO  Cheers !
Post by Iseneschalon Feb 04, 2021 10:21am

My thoughts for KMPH....

We're currently trading at ~ $7.50 this a.m........... We've been here before....which was last Jan25th. I'd like to see a break of this level because I feel that we could fill the gap ...more  
Post by Iseneschalon Feb 04, 2021 8:33am

Movin on up.......

in this a.m's Pre-market open....just sayin! My last post was a gift IMHO.......did u BTFD ?? Just added this a.m...... in other words I am re-loading Here and will add on weakness.  ...more  
Post by Iseneschalon Jan 28, 2021 12:07pm

Just added this a.m......

in other words I am re-loading Here and will add on weakness.  Cheers !
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities